Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026
HCPCS J1837 · per 1 MG

Inj, posaconazole, 1 mg

Products billed under this code include Posaconazole.

Payment limit per 1 MG, by effective quarter, 1Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J1837

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Posaconazole Endo USA, Inc. 42023-0195-01 300 $115.50
Posaconazole Eugia US LLC 55150-0388-01 300 $115.50
Posaconazole FreseniUS Kabi USA, LLC 63323-0685-17 300 $115.50
Posaconazole Mylan Institutional LLC 67457-0665-20 300 $115.50
Posaconazole Glenmark Pharmaceuticals Inc., USA 68462-0904-01 300 $115.50
Posaconazole Glenmark Pharmaceuticals Inc., USA 68462-0911-01 300 $115.50

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $0.385 +$0.043 1 MG Inj, posaconazole, 1 mg v1, posted September 17, 2026
3Q26 $0.342 −$0.005 1 MG Inj, posaconazole, 1 mg v1, posted September 15, 2026
2Q26 $0.347 +$0.001 1 MG Inj, posaconazole, 1 mg v1, posted September 15, 2026
1Q26 $0.346 – 1 MG Inj, posaconazole, 1 mg v1, posted September 15, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files